Summary & Overview
HCPCS J7352: Afamelanotide Implant, 1 mg
HCPCS Level II code J7352 identifies an afamelanotide implant, 1 mg, a targeted pharmaceutical implant used in outpatient settings. Nationally, this code matters because it standardizes billing for a specialized drug-device therapy administered as a subcutaneous implant and supports consistent claims processing across payers and delivery sites. The code facilitates visibility into utilization, prior authorization workflows, and payment policies for a high-cost implant-based therapy.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage and payment considerations across major payers, benchmarking context where available, common billing practices, and the clinical setting in which the product is typically administered. The publication also summarizes policy updates, coding usage guidance, and payer-specific coverage trends when provided by insurers.
This report is intended for billing managers, revenue cycle professionals, clinicians involved in implant administration, and policy analysts seeking a national perspective on coding, coverage, and administrative implications for J7352. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J7352 represents an afamelanotide implant, 1 mg. This code describes a pharmaceutical implant formulation of afamelanotide delivered as a discrete, single-dose product intended for therapeutic use.
Service Type: Drug administration via subcutaneous implant
Typical Site of Service: Outpatient infusion center, ambulatory surgical center, or outpatient clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with erythropoietic protoporphyria (EPP) or other photodermatoses for whom implantation of a sustained-release afamelanotide subcutaneous implant (J7352, Afamelanotide implant, 1 mg) is indicated to increase melanin production and reduce phototoxic reactions. The clinical workflow begins with a documented diagnosis and specialty consultation (commonly dermatology or clinical genetics). Pre-procedure evaluation includes history of phototoxic episodes, medication review, pregnancy test if applicable, and counseling on risks and benefits. The implant is delivered by an appropriately credentialed provider in an outpatient clinic, ambulatory surgery center, or physician office. Local anesthesia may be used; the implant is inserted subcutaneously in the lower abdominal wall or buttock region through a small incision or trocar. Post-procedure monitoring is brief for bleeding or local reaction; the patient receives wound care instructions and scheduled follow-up for clinical response and potential repeat dosing at manufacturer-recommended intervals. Billing for the drug uses the HCPCS Level II code J7352; facility or professional service charges and any related procedural codes are reported separately with appropriate modifiers as clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier |